Skip to main content

Tweed's VP and general counsel, Mark Zekulin, inside the grow room, home to the company's mother plants.

eugen sakhnenko The Globe and Mail

Tweed Marijuana Inc. is setting up as a win for its early backers, with shares of the company opening their first day of trading far higher than expected.

Shares of Tweed began trading at $4.60 on the TSX Venture exchange, before falling back to the $2.60 range. Either way, that's a big jump.

Tweed executive chairman Bruce Linton told the Huffington Post that he thought the shares would open around 85 cents a piece. The last private financing round was done at just a month ago at the equivalent of 89 cents a share. GMP Securities, which is Tweed's main advisor, arranged that round as well as earlier ones.

Story continues below advertisement

The company went public via a combination with a shell company. It now trades under the ticker "TWD" on the venture market.

Medicinal marijuana deals have a lot of buzz right now, with growers looking to take advantage of licenses to supply the federal government with the drug. Tweed has a growing operation in a former chocolate plant near Ottawa.

Investors are moving back into riskier, smaller ventures in a big way, as evidenced by the interest in Tweed and the huge order book for the pending Lumenpulse Lighting IPO. Lumenpulse now has more than $1-billion of orders for $75-million of stock on sale, with the books set to close at midday Friday.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies